SII Testing under the SI 60601 Series

Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Active electrical devices in Israel may need to be assessed by the Standards Institution of Israel (SII) under the SI 60601 series (electrical safety and electromagnetic compatibility). The SII accepts CB certificates and EMC reports issued by accredited laboratories, which can significantly compress the testing timeline. From 1 January 2025, the SII has rolled out an import reform: products that comply with European Union legislation, or that are already lawfully marketed in the EU, may be exempted from standards testing, with a declaration of conformity substituting for the test certificate; the reform proceeds by product category in phases through 2028. Whether medical devices have been brought within the current category list must be verified category by category (practical estimate).

  • SII testing is a second customs-clearance track running in parallel with AMAR registration, and it is the most common time sink at the import stage.
  • CB certificates plus accredited-laboratory EMC reports are accepted by the SII and avoid duplicate sample submission.
  • The import reform works by amending the applicability of the Standards Law product by product, so country of origin is not the deciding factor — CE-marked goods made in China may in principle benefit.
  • Food, motor vehicles and certain firefighting equipment are expressly outside the reform; medical devices must be checked against the current category list.

2. Legal basis

The table below records the testing requirements, the SI 60601 series, the import reform timeline and the parent law.

Regulation nameStandards Institution of Israel (SII) electrical and electronics laboratory testing requirements; SI 60601 series standards
Reference / numberSI 60601 series (corresponding to the IEC 60601 series)
Publication dateThe SII import reform is implemented in phases from 1 January 2025, to be completed by 2028
ProvisionsRequirements clauses for electrical safety and EMC assessment; import reform clauses on EU conformity as sufficient (applied by amending the 1953 Standards Law product by product)
Parent lawMedical Equipment Law, 5772-2012 (14 May 2012), Article 6(a) (proper manufacturing conditions, quality fit for intended use)
Practical estimateThe reform does not apply to food, motor vehicles and specific firefighting equipment; whether medical devices are covered must be verified category by category against the current list

3. Expert insights

SII testing is the second clearance pathway that exists alongside device regulation. Completing registration does not mean the equipment can enter the country — active electrical products must still pass the SII. Running the two pathways in parallel rather than in sequence is the central scheduling decision, because a serial plan is the most common black hole for time in the import phase.

The key to compressing the timeline lies in using the CB certificate. Test reports and certificates issued under the CB Scheme (IECEE) are accepted by the SII, and combined with EMC reports from accredited laboratories they avoid submitting samples twice. GRZAN’s recommendation is to require the laboratory to issue a combined CB report plus EMC report at the CE certification stage, rather than only the documents needed for EU conformity — the incremental cost is limited, but the reuse value for Israel and other markets is high. Deciding this before the testing plan is signed is what locks in the saving; asking for it afterwards means re-opening the project with the laboratory.

The SII import reform beginning in 2025 deserves separate attention. Its mechanism is to amend the applicability of the Standards Law product by product, without setting limits by country of origin — products manufactured in China but bearing a valid CE mark can in principle benefit equally, although they must still submit a declaration of conformity in place of the test certificate. GRZAN flags two points: first, the reform proceeds by category in phases (standards categories from 1 January 2025, energy categories from 1 November 2024, and so on); second, food, motor vehicles and specific firefighting equipment are expressly excluded. The status of medical devices must be confirmed against the SII’s current announcements (practical estimate), because category lists are updated as the phased rollout continues.

The practical conclusion is that the applicability check belongs at the very front of the project, at the same time as the registration pathway decision, since it determines whether a test campaign or a declaration file is the export deliverable.

4. Practical recommendations

  • Lock in the CB plus EMC reports at the certification stage. Request them at the same time as CE certification to avoid a second round of sample submission.
  • Verify reform applicability category by category. Confirm with the SII or the Israeli registration holder (IRH) whether the category of the product under application has been brought within the reform list.
  • Schedule the two pathways in parallel. Start AMAR registration and SII testing at the same time rather than one after the other.
  • Prepare the declaration of conformity template in advance. If the reform applies, draft the declaration of conformity in the form required by the SII ahead of time (practical estimate).

5. Verification checklist

  • □ It has been determined whether the product falls into the active electrical category
  • □ The CB certificate and the accredited laboratory’s EMC report have been obtained
  • □ The specific applicable parts of the SI 60601 series have been confirmed (electrical safety, EMC)
  • □ The product category’s status under the SII import reform list has been verified (practical estimate)
  • □ AMAR registration and SII testing have been scheduled in parallel
  • □ A declaration of conformity template has been prepared to SII requirements (where the reform applies)

Regulatory information verified as of 29 October 2026. The regulation names, numbers, publication dates and provisions cited in this article were checked against the official Israeli legal databases and authoritative public sources on that date; AMAR procedural documents are updated frequently, so before any formal submission the current version on the Ministry of Health website prevails.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Israeli market. Our team prepares MOH-compliant dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail